Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hewei Anchang Formula for Overlapping FD and IBS-D
NCT07715760Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jan 2027
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial in functional dyspepsia (FD) and Irritable bowel syndrome with diarrhea (IBS-D) comparing Hewei Anchang Formula Group with Placebo Group (2 arms). Primary endpoints: Functional Dyspepsia Symptom Severity Scale Scores at 8 weeks, Global Impression Scale for Dyspepsia Symptom Relief at 8 weeks and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Hewei Anchang Formula
03
Conditions
functional dyspepsia (FD)Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07715760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715760.